Complications and comorbidities of type 2 diabetes

Pediatric Annals

Volumn 34, Issue 9, 2005, Pages 711-718

  Norris, Andrew W ^a,b,c,d   Svoren, Britta M ^b,c  

^a JOSLIN DIABETES CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; CREATININE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LABETALOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METOPROLOL; ORAL ANTIDIABETIC AGENT; POTASSIUM; RESIN; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNINDEXED DRUG;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSENSUS; CORONARY ARTERY DISEASE; DIABETES CONTROL; DIABETIC ANGIOPATHY; DIABETIC MACROANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DRUG CHOICE; DRUG DOSE REGIMEN; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KINESIOTHERAPY; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LIVER INJURY; LIVER TOXICITY; METABOLIC SYNDROME X; NECROBIOSIS LIPOIDICA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; STROKE; TERATOGENICITY; WEIGHT REDUCTION; ADOLESCENT; ARTICLE; CHILD;

ADOLESCENT; BLOOD GLUCOSE; CHILD; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; HYPERTENSION; METABOLIC SYNDROME X; PREDIABETIC STATE; RISK FACTORS;

EID: 84861253909     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/0090-4481-20050901-11     Document Type: Review

References (29)

1. Pinhas-Hamiel O, Dolan LM, Daniels SR, et al. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128(5 Pt 1):608-615.
2. Sinha R, Fisch G, Teague B, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J med. 2002;346(11):802-810.
3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):703-713.
4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-865.
5. Vaccaro O, Imperatore G, Iovino V, et al. Does impaired glucose tolerance predict hypertension? A prospective analysis. Diabetologia. 1996;39(1):70-76.
6. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002;40(4):441-447.
7. Alberti G, Zimmet P, Shaw J, et al.; Consensus Workshop Group. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004;27(7): 1798-1811.
8. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555-576.
9. Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321(9):580-585.
10. Rocchini AP, Katch V, Anderson J, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics. 1988;82(1):16-23.
11. Miller K. Pharmacological management of hypertension in paediatric patients. A comprehensive review of the efficacy, safety and dosage guidelines of the available agents. Drugs. 1994;48(6):868-887.
12. American Diabetes Association. Management of dyslipidemia in children and adolescents with diabetes. Diabetes Care. 2003; 26(7):2194-2197.
13. Branchi A, Rovellini A, Torri A, Sommariva D. Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients. Diabetes Care. 1998;21(9):1397-1402.
14. Kavey RE, Daniels SR, Lauer RM, et al.; American Heart Association. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003; 107(11):1562-1566.
15. de Jongh S, Ose L, Szamosi T, et al.; Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106(17):2231-2237.
16. Jonas MM. Nonalcoholic fatty liver disease. Adolesc Med Clin. 2004;15(1):159-173, xi.
17. Cook S, Weitzman M, Auinger P, Nguyen M, Dietz WH. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003;157(8):821-827.
18. Strauss RS, Barlow SE, Dietz WH. Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr. 2000;136(6):727-733.
19. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004;20(1):23-28.
20. Duseja A, Murlidharan R, Bhansali A, et al. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis - a preliminary report. Indian J Gastroenterol. 2004;23(1):12-15.
21. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358(9285):893-894.
22. Genuth S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160-3167.
23. Wiegand S, Maikowski U, Blankenstein O, et al. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity - a problem that is no longer restricted to minority groups. Eur J Endocrinol. 2004;151(2):199-206.
24. Reinehr T, Andler W, Kapellen T, et al. Clinical characteristics of type 2 diabetes mellitus in overweight European Caucasian adolescents. Exp Clin Endocrinol Diabetes. 2005;113(3):167-170.
25. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
26. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.
27. Bao W, Srinivasan SR, Berenson GS. Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study. Circulation. 1996;93(1):54-59.
28. Weiss R, Dziura J, Burgert T, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004;350(23):2362-2374.
29. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290(17):2277-2283.